{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:41:51Z","timestamp":1785840111857,"version":"3.56.0"},"reference-count":68,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Ribavirin has been used as an antiviral agent to treat a variety of viral infections since\nthe 1970s. Over the past few decades, studies have been conducted on the pharmacology of ribavirin,\nand the possibility of its use in new indications has been explored. According to the results\nof a number of studies, ribavirin efficacy in the therapy of malignant neoplasms of various genesis\nhas been proven. Furthermore, due to the complexity of brain tumor therapy using surgical methods,\ntargeted delivery of ribavirin to the brain becomes a promising alternative to existing treatment\nmethods. Targeting of active pharmaceutical ingredient (API) to the brain tumor is achieved\nby intranasal drug delivery via a Nose-to-Brain mechanism. In addition, using this delivery mechanism,\nit is possible to reach the brain while bypassing the blood-brain barrier (BBB), thus avoiding\nthe effects of the first passage through the liver. Despite the significant advantages of the\nmethod, there are limiting factors to its application - mucociliary clearance, which aims to remove\nforeign bodies from the surface of the nasal mucosa. &lt;i&gt;In situ&lt;\/i&gt;, systems are able to reduce the intensity\nof interfering factors on API and allow the achievement of maximum bioavailability during intranasal\nadministration.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115672018305548240614113451","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T06:13:56Z","timestamp":1724825636000},"page":"510-521","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ribavirin in Modern Antitumor Therapy: Prospects for Intranasal Administration"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-0049","authenticated-orcid":true,"given":"Iosif","family":"Mikhel","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-0346","authenticated-orcid":true,"given":"Elena","family":"Bakhrushina","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State\nMedical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-3727","authenticated-orcid":true,"given":"Olga","family":"Stepanova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy,\nI.M. Sechenov First Moscow State Medical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Prilepskaya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State\nMedical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Kosenkov","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry,\nI.M. Sechenov First Moscow State Medical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8214-4483","authenticated-orcid":true,"given":"Anastasia","family":"Belyatskaya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State\nMedical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigory","family":"Evzikov","sequence":"additional","affiliation":[{"name":"Department of Nervous Diseases\nand Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical\nUniversity, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-8791","authenticated-orcid":true,"given":"Natalia","family":"Demina","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State\nMedical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-8829","authenticated-orcid":true,"given":"Ivan","family":"Krasnyuk","sequence":"additional","affiliation":[{"name":"Department of Analytical, Physical and Colloidal Chemistry, A.P. Nelyubin Institute\nof Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-2988","authenticated-orcid":true,"given":"Ivan","family":"Krasnyuk","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State\nMedical University, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.18413\/2313-8955-2015-1-4-79-86","volume":"1","author":"Golivets T.P.","year":"2015","unstructured":"Golivets T.P.; Kovalenko B.S.; Analysis of world and russian trends in cancer incidence in the twenty-first century.research result. Med Pharm Ser  2015,1","journal-title":"Med Pharm Ser"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.177.4050.705","volume":"177","author":"Sidwell R.W.","year":"1972","unstructured":"Sidwell R.W.; Huffman J.H.; Khare G.P.; Allen L.B.; Witkowski J.T.; Robins R.K.; Broad-spectrum antiviral activity of Virazole: 1-\u03b2-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science  1972,177(4050),705-706","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1021\/jm00281a014","volume":"15","author":"Witkowski J.T.","year":"1972","unstructured":"Witkowski J.T.; Robins R.K.; Sidwell R.W.; Simon L.N.; Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem  1972,15(11),1150-1154","journal-title":"J Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1128\/AAC.3.2.235","volume":"3","author":"Huffman J.H.","year":"1973","unstructured":"Huffman J.H.; Sidwell R.W.; Khare G.P.; Witkowski J.T.; Allen L.B.; Robins R.K.; In vitro effect of 1-\u03b2-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother  1973,3(2),235-241","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/0091270004262974","volume":"44","author":"Lin C.C.","year":"2004","unstructured":"Lin C.C.; Philips L.; Xu C.; Yeh L.T.; Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol  2004,44(3),265-275","journal-title":"J Clin Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/INF.0b013e31821c922c","volume":"30","author":"McJunkin J.E.","year":"2011","unstructured":"McJunkin J.E.; Nahata M.C.; De Los Reyes E.C.; Hunt W.G.; Caceres M.; Khan R.R.; Chebib M.G.; Taravath S.; Minnich L.L.; Carr R.; Welch C.A.; Whitley R.J.; Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr Infect Dis J  2011,30(10),860-865","journal-title":"Pediatr Infect Dis J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/liv.12114","volume":"33","author":"Pischke S.","year":"2013","unstructured":"Pischke S.; Hardtke S.; Bode U.; Birkner S.; Chatzikyrkou C.; Kauffmann W.; Bara C.L.; Gottlieb J.; Wenzel J.; Manns M.P.; Wedemeyer H.; Ribavirin treatment of acute and chronic hepatitis E: A single\u2010centre experience. Liver Int  2013,33(5),722-726","journal-title":"Liver Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"Hopkins A.L.","year":"2008","unstructured":"Hopkins A.L.; Network pharmacology:The next paradigm in drug discovery. Nat Chem Biol  2008,4(11),682-690","journal-title":"Nat Chem Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0091-6749(86)90057-6","volume":"78","author":"Levy G.","year":"1986","unstructured":"Levy G.; Kinetics of drug action: An overview. J Allergy Clin Immunol  1986,78(4),754-761","journal-title":"J Allergy Clin Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.33380\/2305-2066-2021-10-4-117-127","volume":"10","author":"Porfiryeva N.N.","year":"2021","unstructured":"Porfiryeva N.N.; Semina I.I.; Moustafine R.I.; Khutoryanskiy V. V.; Intranasal administration as a route to deliver drugs to the brain (Review). Drug develop regist  2021,10,117-127","journal-title":"Drug develop regist"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.bbrc.2018.10.124","volume":"506","author":"Chen J.","year":"2018","unstructured":"Chen J.; Xu X.; Chen J.; Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. Biochem Biophys Res Commun  2018,506(3),604-610","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e0225860","DOI":"10.1371\/journal.pone.0225860","volume":"14","author":"Wambecke A.","year":"2019","unstructured":"Wambecke A.; Laurent-Issartel C.; Leroy-Dudal J.; Giffard F.; Cosson F.; Lubin-Germain N.; Uziel J.; Kellouche S.; Carreiras F.; Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells. PLoS One  2019,14(12),e0225860","journal-title":"PLoS One"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.bbrc.2018.06.150","volume":"503","author":"Xi C.","year":"2018","unstructured":"Xi C.; Wang L.; Yu J.; Ye H.; Cao L.; Gong Z.; Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer. Biochem Biophys Res Commun  2018,503(4),2286-2292","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=14","author":"Me\u0161trovi\u0107 T.","unstructured":"Me\u0161trovi\u0107 T.; Ribavirin Chemistry.  Available from:  https:\/\/www.news-medical.net\/health\/Ribavirin-Chemistry.aspx (accessed on 29-5-2024)."},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.18632\/oncotarget.23883","volume":"9","author":"Casaos J.","year":"2018","unstructured":"Casaos J.; Huq S.; Lott T.; Felder R.; Choi J.; Gorelick N.; Peters M.; Xia Y.; Maxwell R.; Zhao T.; Ji C.; Simon T.; Sesen J.; Scotland S.J.; Kast R.E.; Rubens J.; Raabe E.; Eberhart C.G.; Jackson E.M.; Brem H.; Tyler B.; Skuli N.; Ribavirin as a potential therapeutic for atypical teratoid\/rhabdoid tumors. Oncotarget  2018,9(8),8054-8067","journal-title":"Oncotarget"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3892\/or.2015.3816","volume":"33","author":"De La Cruz-Hernandez E.","year":"2015","unstructured":"De La Cruz-Hernandez E.; Medina-Franco J.L.; Trujillo J.; Chavez-Blanco A.; Dominguez-Gomez G.; Perez-Cardenas E.; Gonzalez-Fierro A.; Taja-Chayeb L.; Due\u00f1as-Gonzalez A.; Ribavirin as a tri-targeted antitumor repositioned drug. Oncol Rep  2015,33(5),2384-2392","journal-title":"Oncol Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amjms.2017.03.025","volume":"354","author":"Shen X.","year":"2017","unstructured":"Shen X.; Zhu Y.; Xiao Z.; Dai X.; Liu D.; Li L.; Xiao B.; Antiviral drug ribavirin targets thyroid cancer cells by inhibiting the eIF4E-\u03b2-catenin axis. Am J Med Sci  2017,354(2),182-189","journal-title":"Am J Med Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41388-018-0567-7","volume":"38","author":"Urtishak K.A.","year":"2019","unstructured":"Urtishak K.A.; Wang L.S.; Culjkovic-Kraljacic B.; Davenport J.W.; Porazzi P.; Vincent T.L.; Teachey D.T.; Tasian S.K.; Moore J.S.; Seif A.E.; Jin S.; Barrett J.S.; Robinson B.W.; Chen I.M.L.; Harvey R.C.; Carroll M.P.; Carroll A.J.; Heerema N.A.; Devidas M.; Dreyer Z.E.; Hilden J.M.; Hunger S.P.; Willman C.L.; Borden K.L.B.; Felix C.A.; Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene  2019,38(13),2241-2262","journal-title":"Oncogene"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.yexcr.2016.11.001","volume":"350","author":"Isakovic A.M.","year":"2017","unstructured":"Isakovic A.M.; Dulovic M.; Markovic I.; Kravic-Stevovic T.; Bumbasirevic V.; Trajkovic V.; Isakovic A.; Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic death. Exp Cell Res  2017,350(1),32-40","journal-title":"Exp Cell Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3892\/or.2017.6149","volume":"2017","author":"Ochiai Y.","year":"2017","unstructured":"Ochiai Y.; Sano E.; Okamoto Y.; Yoshimura S.; Makita K.; Yamamuro S.; Ohta T.; Ogino A.; Tadakuma H.; Ueda T.; Nakayama T.; Hara H.; Yoshino A.; Katayama Y.; Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. Oncol Rep  2017,2017,537-544","journal-title":"Oncol Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3892\/ol.2014.2569","volume":"8","author":"Ogino A.","year":"2014","unstructured":"Ogino A.; Sano E.; Ochiai Y.; Yamamuro S.; Tashiro S.; Yachi K.; Ohta T.; Fukushima T.; Okamoto Y.; Tsumoto K.; Ueda T.; Yoshino A.; Katayama Y.; Efficacy of ribavirin against malignant glioma cell lines. Oncol Lett  2014,8(6),2469-2474","journal-title":"Oncol Lett"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"Liang T.","year":"2023","unstructured":"Liang T.; Wang F.; Elhassan R.M.; Cheng Y.; Tang X.; Chen W.; Fang H.; Hou X.; Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B  2023,13(6),2425-2463","journal-title":"Acta Pharm Sin B"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3171\/2020.8.PEDS20561","volume":"27","author":"Huq S.","year":"2021","unstructured":"Huq S.; Kannapadi N.V.; Casaos J.; Lott T.; Felder R.; Serra R.; Gorelick N.L.; Ruiz-Cardozo M.A.; Ding A.S.; Cecia A.; Medikonda R.; Ehresman J.; Brem H.; Skuli N.; Tyler B.M.; Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma. J Neurosurg Pediatr  2021,27(4),482-488","journal-title":"J Neurosurg Pediatr"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-18-0666","volume":"18","author":"Casaos J.","year":"2019","unstructured":"Casaos J.; Gorelick N.L.; Huq S.; Choi J.; Xia Y.; Serra R.; Felder R.; Lott T.; Kast R.E.; Suk I.; Brem H.; Tyler B.; Skuli N.; The use of ribavirin as an anticancer therapeutic: Will it go viral? Mol Cancer Ther  2019,18(7),1185-1194","journal-title":"Mol Cancer Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.bbrc.2019.01.117","volume":"510","author":"Jin J.","year":"2019","unstructured":"Jin J.; Xiang W.; Wu S.; Wang M.; Xiao M.; Deng A.; Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer. Biochem Biophys Res Commun  2019,510(4),580-586","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/onc.2016.457","volume":"36","author":"Volpin F.","year":"2017","unstructured":"Volpin F.; Casaos J.; Sesen J.; Mangraviti A.; Choi J.; Gorelick N.; Frikeche J.; Lott T.; Felder R.; Scotland S.J.; Eisinger-Mathason T.S.K.; Brem H.; Tyler B.; Skuli N.; Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene  2017,36(21),3037-3047","journal-title":"Oncogene"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1010428317699797","DOI":"10.1177\/1010428317699797","volume":"39","author":"Kast R.E.","year":"2017","unstructured":"Kast R.E.; Hill Q.A.; Wion D.; Mellstedt H.; Focosi D.; Karpel-Massler G.; Heiland T.; Halatsch M.E.; Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumour Biol  2017,39(5),1010428317699797","journal-title":"Tumour Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"Crowe T.P.","year":"2018","unstructured":"Crowe T.P.; Greenlee M.H.W.; Kanthasamy A.G.; Hsu W.H.; Mechanism of intranasal drug delivery directly to the brain. Life Sci  2018,195,44-52","journal-title":"Life Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/jpet.119.258152","volume":"370","author":"Wang Z.","year":"2019","unstructured":"Wang Z.; Xiong G.; Tsang W.C.; Sch\u00e4tzlein A.G.; Uchegbu I.F.; Nose-to-Brain Delivery. J Pharmacol Exp Ther  2019,370(3),593-601","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"Daneman R.","year":"2015","unstructured":"Daneman R.; Prat A.; The blood-brain barrier. Cold Spring Harb Perspect Biol  2015,7(1),a020412","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"120250","DOI":"10.1016\/j.ijpharm.2021.120250","volume":"597","author":"Qu Y.","year":"2021","unstructured":"Qu Y.; Li A.; Ma L.; Iqbal S.; Sun X.; Ma W.; Li C.; Zheng D.; Xu Z.; Zhao Z.; Ma D.; Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. Int J Pharm  2021,597,120250","journal-title":"Int J Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ar.25230","volume":"2023","author":"N\u00fa\u00f1ez\u2010Cook S.","year":"2023","unstructured":"N\u00fa\u00f1ez\u2010Cook S.; Vidal\u2010Mugica F.; Salinas P.; Anatomy and computed tomography of the nasal cavity, nasal conchae, and paranasal sinuses of the endangered patagonian huemul deer (Hippocamelus Bisulcus). Anat Rec  2023,2023,141-154","journal-title":"Anat Rec"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.coms.2012.01.011","volume":"24","author":"Ogle O.E.","year":"2012","unstructured":"Ogle O.E.; Weinstock R.J.; Friedman E.; Surgical anatomy of the nasal cavity and paranasal sinuses. Oral Maxillofac Surg Clin North Am  2012,24(2),155-166","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1042986","DOI":"10.3389\/fbioe.2022.1042986","volume":"10","author":"Cao Y.","year":"2022","unstructured":"Cao Y.; Zhang R.; The application of nanotechnology in treatment of Alzheimer\u2019s disease. Front Bioeng Biotechnol  2022,10,1042986","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejpb.2020.05.001","volume":"152","author":"Kanazawa T.","year":"2020","unstructured":"Kanazawa T.; Taki H.; Okada H.; Nose-to-brain drug delivery system with ligand\/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas. Eur J Pharm Biopharm  2020,152,85-94","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.drudis.2019.10.005","volume":"25","author":"Sabir F.","year":"2020","unstructured":"Sabir F.; Ismail R.; Csoka I.; Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discov Today  2020,25(1),185-194","journal-title":"Drug Discov Today"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"120002","DOI":"10.1016\/j.ijpharm.2020.120002","volume":"591","author":"Ma J.","year":"2020","unstructured":"Ma J.; Wang C.; Sun Y.; Pang L.; Zhu S.; Liu Y.; Zhu L.; Zhang S.; Wang L.; Du L.; Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia. Int J Pharm  2020,591,120002","journal-title":"Int J Pharm"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/1061186X.2021.1961790","volume":"30","author":"Liu J.","year":"2022","unstructured":"Liu J.; Li Y.; Liu S.; Zhang Y.; Luo Y.; Yang Y.; Zhuang X.; Wang X.; Zhao B.; Xu T.; Xu L.; Alkoxy cyanoacrylate-based nanoparticles with stealth and brain-targeting properties. J Drug Target  2022,30(2),219-231","journal-title":"J Drug Target"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3390\/pharmaceutics14091870","volume":"14","author":"Alabsi W.","year":"2022","unstructured":"Alabsi W.; Eedara B.B.; Encinas-Basurto D.; Polt R.; Mansour H.M.; Nose-to-brain delivery of therapeutic peptides as nasal aerosols. Pharmaceutics  2022,14(9),1870","journal-title":"Pharmaceutics"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0361-9230(85)90129-7","volume":"15","author":"Shipley M.T.","year":"1985","unstructured":"Shipley M.T.; Transport of molecules from nose to brain: Transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull  1985,15(2),129-142","journal-title":"Brain Res Bull"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0166-3542(87)80002-5","volume":"8","author":"Smith A.L.","year":"1987","unstructured":"Smith A.L.; Barthold S.W.; Beck D.S.; Intranasally administered alpha\/beta interferon prevents extension of mouse hepatitis virus, strain JHM, into the brains of BALB\/cByJ mice. Antiviral Res  1987,8(5-6),239-245","journal-title":"Antiviral Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","volume":"692","author":"Thorne R.G.","year":"1995","unstructured":"Thorne R.G.; Emory C.R.; Ala T.A.; Frey W.H.; Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res  1995,692(1-2),278-282","journal-title":"Brain Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/10611869909085506","volume":"7","author":"Sakane T.","year":"1999","unstructured":"Sakane T.; Yamashita S.; Yata N.; Sezaki H.; Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target  1999,7(3),233-240","journal-title":"J Drug Target"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","volume":"344","author":"Kurano T.","year":"2022","unstructured":"Kurano T.; Kanazawa T.; Ooba A.; Masuyama Y.; Maruhana N.; Yamada M.; Iioka S.; Ibaraki H.; Kosuge Y.; Kondo H.; Suzuki T.; Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties. J Control Release  2022,344,225-234","journal-title":"J Control Release"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/jfb13030125","volume":"13","author":"Montegiove N.","year":"2022","unstructured":"Montegiove N.; Calzoni E.; Emiliani C.; Cesaretti A.; Biopolymer nanoparticles for nose-to-brain drug delivery: A new promising approach for the treatment of neurological diseases. J Funct Biomater  2022,13(3),125","journal-title":"J Funct Biomater"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.antiviral.2011.09.012","volume":"92","author":"Colombo G.","year":"2011","unstructured":"Colombo G.; Lorenzini L.; Zironi E.; Galligioni V.; Sonvico F.; Balducci A.G.; Pagliuca G.; Giuliani A.; Calz\u00e0 L.; Scagliarini A.; Brain distribution of ribavirin after intranasal administration. Antiviral Res  2011,92(3),408-414","journal-title":"Antiviral Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/10717544.2018.1428242","volume":"25","author":"Giuliani A.","year":"2018","unstructured":"Giuliani A.; Balducci A.G.; Zironi E.; Colombo G.; Bortolotti F.; Lorenzini L.; Galligioni V.; Pagliuca G.; Scagliarini A.; Calz\u00e0 L.; Sonvico F.; In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv  2018,25(1),376-387","journal-title":"Drug Deliv"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/pharmaceutics13081126","volume":"13","author":"Vasa D.M.","year":"2021","unstructured":"Vasa D.M.; Bakri Z.; Donovan M.D.; O\u2019Donnell L.A.; Wildfong P.L.D.; Evaluation of ribavirin\u2013poloxamer microparticles for improved intranasal absorption. Pharmaceutics  2021,13(8),1126","journal-title":"Pharmaceutics"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"Craft S.","year":"2012","unstructured":"Craft S.; Baker L.D.; Montine T.J.; Minoshima S.; Watson G.S.; Claxton A.; Arbuckle M.; Callaghan M.; Tsai E.; Plymate S.R.; Green P.S.; Leverenz J.; Cross D.; Gerton B.; Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol  2012,69(1),29-38","journal-title":"Arch Neurol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2017.11.041","volume":"270","author":"Godfrey L.","year":"2018","unstructured":"Godfrey L.; Iannitelli A.; Garrett N.L.; Moger J.; Imbert I.; King T.; Porreca F.; Soundararajan R.; Lalatsa A.; Sch\u00e4tzlein A.G.; Uchegbu I.F.; Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. J Control Release  2018,270,135-144","journal-title":"J Control Release"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","volume":"152","author":"Thorne R.G.","year":"2008","unstructured":"Thorne R.G.; Hanson L.R.; Ross T.M.; Tung D.; Frey W.H.; Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration. Neuroscience  2008,152(3),785-797","journal-title":"Neuroscience"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.33380\/2305-2066-2021-10-4-54-63","volume":"10","author":"Bakhrushina E.O.","year":"2021","unstructured":"Bakhrushina E.O.; Demina N.B.; Shumkova M.M.; Rodyuk P.S.; Shulikina D.S.; Krasnyuk I.I.; In Situ intranasal delivery systems: application prospects and main pharmaceutical aspects of development (Review). Drug develop regist  2021,10,54-63","journal-title":"Drug develop regist"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10517-023-05704-6","volume":"174","author":"Bakhrushina E.O.","year":"2023","unstructured":"Bakhrushina E.O.; Mikhel I.B.; Pyzhov V.S.; Demina N.B.; Krasnyuk I.I.; Krasnyuk I.I.; Development of in situ intranasal system based on chitosan formate. Bull Exp Biol Med  2023,174(3),337-340","journal-title":"Bull Exp Biol Med"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.2174\/0113892010260017231002075152","volume":"25","author":"Bakhrushina E.O.","year":"2023","unstructured":"Bakhrushina E.O.; Mikhel I.B.; Pyzhov V.S.; Demina N.B.; Krasnyuk I.I.; Krasnyuk I.I.; Main aspects of pharmaceutical development of in situ immunobiological drugs for intranasal administration. Curr Pharm Biotechnol  2023,25","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.apsb.2021.01.014","volume":"11","author":"Pang L.","year":"2021","unstructured":"Pang L.; Zhu S.; Ma J.; Zhu L.; Liu Y.; Ou G.; Li R.; Wang Y.; Liang Y.; Jin X.; Du L.; Jin Y.; Intranasal temperature-sensitive hydrogels of cannabidiol inclusion complex for the treatment of post-traumatic stress disorder. Acta Pharm Sin B  2021,11(7),2031-2047","journal-title":"Acta Pharm Sin B"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"119384","DOI":"10.1016\/j.ijpharm.2020.119384","volume":"583","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Pang L.; Zhu S.; Ma J.; Li R.; Liu Y.; Zhu L.; Zhuang X.; Zhi W.; Yu X.; Du L.; Zuo H.; Jin Y.; Intranasal tetrandrine temperature-sensitive in situ hydrogels for the treatment of microwave-induced brain injury. Int J Pharm  2020,583,119384","journal-title":"Int J Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"123566","DOI":"10.1016\/j.ijpharm.2023.123566","volume":"648","author":"Gadhave D.","year":"2023","unstructured":"Gadhave D.; Quadros M.; Ugale A.R.; Goyal M.; Gupta V.; A Nanoemulgel for Nose-to-Brain delivery of Quetiapine \u2013 QbD-Enabled formulation development  in-vitro characterization. Int J Pharm  2023,648,123566","journal-title":"Int J Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/polym15193890","volume":"15","author":"Badran M.M.","year":"2023","unstructured":"Badran M.M.; Alanazi A.E.; Ibrahim M.A.; Alshora D.H.; Taha E.; H Alomrani A.; Optimization of bromocriptine-mesylate-loaded polycaprolactone nanoparticles coated with chitosan for nose-to-brain delivery: In Vitro and In Vivo studies. Polymers  2023,15(19),3890","journal-title":"Polymers"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.3324\/haematol.2014.111245","volume":"100","author":"Assouline S.","year":"2015","unstructured":"Assouline S.; Culjkovic-Kraljacic B.; Bergeron J.; Caplan S.; Cocolakis E.; Lambert C.; Lau C.J.; Zahreddine H.A.; Miller W.H.; Borden K.L.B.; A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica  2015,100(1),e7-e9","journal-title":"Haematologica"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","volume":"114","author":"Assouline S.","year":"2009","unstructured":"Assouline S.; Culjkovic B.; Cocolakis E.; Rousseau C.; Beslu N.; Amri A.; Caplan S.; Leber B.; Roy D.C.; Miller W.H.; Borden K.L.B.; Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood  2009,114(2),257-260","journal-title":"Blood"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hed.24938","volume":"40","author":"Dunn L.A.","year":"2018","unstructured":"Dunn L.A.; Fury M.G.; Sherman E.J.; Ho A.A.; Katabi N.; Haque S.S.; Pfister D.G.; Phase I.; Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA\/IVB human papillomavirus\u2010associated oropharyngeal squamous cell cancer. Head Neck  2018,40(2),233-241","journal-title":"Head Neck"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/MEG.0000000000001152","volume":"30","author":"Hassany M.","year":"2018","unstructured":"Hassany M.; Elsharkawy A.; Maged A.; Mehrez M.; Asem N.; Gomaa A.; Mostafa Z.; Abbas B.; Soliman M.; Esmat G.; Hepatitis C.; Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol  2018,30(8),876-881","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1111\/jgh.13012","volume":"30","author":"Huang J.F.","year":"2015","unstructured":"Huang J.F.; Yeh M.L.; Yu M.L.; Dai C.Y.; Huang C.F.; Huang C.I.; Tsai P.C.; Lin P.C.; Chen Y.L.; Chang W.T.; Hou N.J.; Lin Z.Y.; Chen S.C.; Chuang W.L.; The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol  2015,30(12),1768-1774","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1461-5347(99)00199-6","volume":"2","author":"Davis S.S.","year":"1999","unstructured":"Davis S.S.; Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm Sci Technol Today  1999,2(11),450-456","journal-title":"Pharm Sci Technol Today"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"Djupesland P.G.","year":"2014","unstructured":"Djupesland P.G.; Messina J.C.; Mahmoud R.A.; The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview. Ther Deliv  2014,5(6),709-733","journal-title":"Ther Deliv"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/MDER.S130900","volume":"11","author":"Tepper S.J.","year":"2018","unstructured":"Tepper S.J.; Johnstone M.R.; Breath-powered sumatriptan dry nasal powder: An intranasal medication delivery system for acute treatment of migraine. Med Devices  2018,11,147-156","journal-title":"Med Devices"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","volume":"7","author":"Arora P.","year":"2002","unstructured":"Arora P.; Sharma S.; Garg S.; Permeability issues in nasal drug delivery. Drug Discov Today  2002,7(18),967-975","journal-title":"Drug Discov Today"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.3390\/molecules24234312","volume":"24","author":"Bruinsmann F.A.","year":"2019","unstructured":"Bruinsmann F.A.; Richter Vaz G.; de Cristo Soares Alves A.; Aguirre T.; Raffin Pohlmann A.; Stanis\u00e7uaski Guterres S.; Sonvico F.; Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: Preclinical and clinical trials. Molecules  2019,24(23),4312","journal-title":"Molecules"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018305548240614113451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233358\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018305548240614113451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:46:16Z","timestamp":1750833976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233358\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018305548240614113451","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}